重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白联合抗风湿药物治疗中重度银屑病的临床观察

目的:观察重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白(rhTNFR:Fc商品名:益赛普)联合抗风湿药物(甲氨蝶呤、来氟米特)治疗中重度银屑病的疗效及安全性。方法:选取本院就诊的78例中重度银屑病患者,其中45例应用rhTNFR:Fc联合甲氨蝶呤、来氟米特治疗为观察组,33例采用单纯抗风湿药物(甲氨喋呤联合来氟米特)治疗为对照组。观察并比较用药前及用药后2周、4周、8周、12周、24周两组的PASI指数及不良反应。结果:治疗8周后两组的PASI50差异有统计学意义(P<0.05),治疗12周及24周后两组PASI50、PASI75、PASI90的比例高于对照组,差异均有统计学意义(P<0.05),两组之间不良反应发生率比较差异无统计学意义(P>0.05)。结论:rhTNFR:Fc联合甲氨蝶呤、来氟米特治疗中重度银屑病疗效显著,值得临床推广。

The observation of rhTNFR:Fc combined with anti rheumatic drugs in the treatment of moderate to severe plaque psoriasis

Objective:To observe the clinical effiency and safety of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein(rhTNFR),combined with anti rheumatic drugs (methotrexate,leflunomide) in treatment of moderate to severe plaque psoriasis.Methods:78 patients of moderate to severe plaque psoriasis treated in our department were selected,45 cases of the observation group treated with rhTNFR:Fc combined with methotrexate (MTX) and leflunomide (LEF),33 cases of the control group treated with MTX + LEF.The severity index scores (PASI) and adverse reaction before treatment and at 2,4,8,12 and 24 weeks after treatment were observed.Results:After 8 weeks of treatment,the difference of PASI50 between the two groups was statistically significant(P ＜ 0.05).After 12 weeks and 24 weeks,the ratio of PASI50,PASI75 and PASI90 in the two groups was significantly higher than that in the control group,and the differences were statistically significant (P ＜ 0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05).Conclusion:It's effective and safety of rhTNFR:Fc combined with MTX and LEF for the treatment of moderate to severe plaque psoriasis,which is worthy of clinical promotion.